{
"@context": "https://schema.org",
"@type": "Article",
"headline": "Litigation vs. Licensing: Manufacturers of the Two Most Recently Approved Biosimilars Take Different Approaches to Reference Drug Patents",
"url": "https://www.mccarter.com/insights/business-litigators-edge-tips-for-litigating-in-new-jersey-federal-and-state-courts/",
"identifier": {
"@type": "PropertyValue",
"name": "LexBlog Library record",
"value": "LEX-WK-N7KKK5JC",
"url": "https://www.lexblog.com/lib/N7KKK5JC/"
},
"datePublished": "2017-12-05T19:39:08-05:00",
"dateModified": "2021-11-09T11:33:36-05:00",
"author": {
"@type": "Person",
"name": "Benjamin R. Holt"
},
"sourceOrganization": {
"@type": "Organization",
"name": "Rothwell Figg"
},
"organizationScope": "at-publication",
"isPartOf": "Biosimilars Law Bulletin",
"about": "Health Care and Life Sciences ยท Intellectual Property",
"sourceUrl": "http://www.biosimilarsip.com/?p=4207",
"sourceStability": "may-move"
}